Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMis Completes $2.2 Million Private Placement

Stockhouse Editorial
0 Comments| January 23, 2019

{{labelSign}}  Favorites
{{errorMessage}}

Biotech Company ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum) on Wednesday announced that it has closed a private placement of 9,560,000 units for gross proceeds of roughly $2,198,800 (CAD). Company President and CEO Elliot Goldstein stated that these funds will - “Allow us to capitalize on the continued interest we are seeing from large pharma in our programs targeting toxic forms of alpha-synuclein for Parkinson's disease (PD) and TDP43 for ALS (amyotrophic lateral sclerosis).”

To find out more, click here.

ProMIS recently stated that Company management will attend the NobleCon15 and the Cantech Investment Conferences to provide overviews of its drug discovery and development programs for Alzheimer's disease, Parkinson's disease and ALS (amyotrophic lateral sclerosis). Management will also participate on discussion panels on Monday, January 28, and Tuesday, January 29, 2019, respectively.


FULL DISCLOSURE: ProMIS Neurosciences Inc. is a client of Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today